12:00 AM
 | 
Apr 08, 2013
 |  BC Week In Review  |  Company News  |  Deals

Biogen Idec, Elan deal

Biogen Idec completed its acquisition of full rights and IP for multiple sclerosis (MS) drug Tysabri natalizumab for $3.3 billion in...

Read the full 82 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >